BACKGROUND The effects of in utero exposure to atypical antipsychotics on infant birth weight are unknown. AIMS To determine whether atypical and typical antipsychotics differ in their effects on birth weight after maternal exposure during pregnancy. METHOD Prospective data on gestational age and birth weight collected by the National Teratology Information Service for infants exposed to ty...

BACKGROUND Several clinical practice guidelines suggest using atypical over typical antipsychotics in patients diagnosed with schizophrenia. Nevertheless, cost-containment policy urged restricting usage of atypical antipsychotics and switching from atypical to typical antipsychotics. OBJECTIVE This study aimed to evaluate clinical and economic impacts of switching from atypical to typical ant...

OBJECTIVE To develop an evidence base for recommendations on the use of atypical antipsychotics for patients with schizophrenia. DESIGN Systematic overview and meta-regression analyses of randomised controlled trials, as a basis for formal development of guidelines. SUBJECTS 12 649 patients in 52 randomised trials comparing atypical antipsychotics (amisulpride, clozapine, olanzapine, quetia...

At present, there are more small, open-label trials than large, double-blind, placebo-controlled studies of atypical antipsychotics in the treatment of nonpsychotic psychiatric illnesses. Existing evidence indicates both the safety and the efficacy of relatively low doses of the dopaminergic/serotonergic atypical antipsychotics as adjunctive, or augmentation, therapy for patients with nonpsycho...

BACKGROUND The extent to which atypical antipsychotics have a lower incidence of extrapyramidal symptoms than typical antipsychotics has not been well-evaluated in community practice. AIMS To examine the effects of switching antipsychotics on antiparkinsonian medication use among individuals with schizophrenia in UK general practices. METHOD We included those switched from typical to atypic...

BACKGROUND Conventional and atypical antipsychotic medications are approved by the FDA for treatment of schizophrenia and bipolar disorder. Over many decades, the widespread use of conventional antipsychotics produced various side effects requiring additional medications, such as the atypical antipsychotics. Beginning in 2006, 9 atypical antipsychotic drugs have been approved by the FDA for ind...

BACKGROUND Previous meta-analyses of atypical antipsychotics for depression were limited by few trials with direct comparisons between two treatments. We performed a network meta-analysis, which integrates direct and indirect evidence from randomized controlled trials (RCTs), to investigate the comparative efficacy and tolerability of adjunctive atypical antipsychotics for treatment-resistant d...

Viewed in the context of ever-expanding conceptual boundaries for the diagnosis of bipolar disorder including the spectrum concept of DSM-IV, or even beyond (Akiskal and Pinto, 1999), it becomes obvious that lithium is the treatment of choice in a minority' of patients only (Bowden et al, 2000). This article reviews what additional benefit atypical antipsychotics may provide in patients with bi...

Background: Sexual dysfunction (SD) is a common occurrence in Schizophrenia on antipsychotics, both typical and atypical. Indian studies this regard are not many number. Aims Objectives: The aims of study were to investigate SD Schizophrenics Trifluoperazine, Risperidone, Olanzapine also evaluate the incidence relation duration illness, treatment, dosage drugs each group subjects. Materials Met...

INTRODUCTION Antipsychotics, particularly atypical antipsychotics, are known to have metabolic side effects such as; weight gain, hyperlipidaemia and insulin resistance. This is problematic as metabolic syndrome can be a precursor to many diseases, including type II diabetes and coronary heart disease. In an attempt to overcome these side-effects, lifestyle changes have been recommended in tand...